Mutations E44D and V118I in the Reverse Transcriptase of HIV-1 Play Distinct Mechanistic Roles in Dual Resistance to AZT and 3TC

This publication has 40 references indexed in Scilit:

• Effects of Specific Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeficiency Virus Type 1 Reverse Transcriptase
  Antimicrobial Agents and Chemotherapy, 2002
• Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase
  Drug Resistance Updates, 2000
• A Mechanism of AZT Resistance
  Molecular Cell, 1999
• Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism
  Proceedings of the National Academy of Sciences, 1998
• Phenotypic Mechanism of HIV-1 Resistance to 3‘-Azido-3‘-deoxythymidine (AZT): Increased Polymerization Processivity and Enhanced Sensitivity to Pyrophosphate of the Mutant Viral Reverse Transcriptase
  Biochemistry, 1998
• Single-Step Kinetics of HIV-1 Reverse Transcriptase Mutants Responsible for Virus Resistance to Nucleoside Inhibitors Zidovudine and 3-TC
  Biochemistry, 1997
• Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
  Science, 1995
• High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
  Antimicrobial Agents and Chemotherapy, 1993
• The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine
  Antimicrobial Agents and Chemotherapy, 1993
• Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
  Antimicrobial Agents and Chemotherapy, 1993